Argus cuts Stryker stock price target on cyberattack impact By Investing.com

Argus cut Stryker’s price target to $350 from $435 while keeping a Buy rating, citing a cyberattack that disrupted Q1 2026 operations and pressured results. Stryker missed Q1 estimates with EPS of $2.60 versus $2.98 expected and revenue of $6.0B versus $6.34B expected, though it reaffirmed 2026 guidance and maintained a $0.88 quarterly dividend, up 4.8% year over year. The stock trades near its 52-week low at $282.58, reflecting recent volatility and setback risk despite longer-term demand and acquisition-driven growth plans.

Analysis

The market is treating this as a one-off execution miss, but the more important signal is that a cyber event can now function like a temporary capacity shock in medtech: even a short disruption can push orders, procedures, and distributor inventory into later quarters. That creates a near-term optics problem and a possible second-order benefit for competitors with cleaner fulfillment and stronger hospital service continuity, especially in elective and device-adjacent categories where buyers can substitute over a 1-2 quarter horizon.

The key question is whether demand was merely delayed or permanently diverted. If management is right that underlying demand remains intact, the setup favors a sharp earnings catch-up in the next 2 reporting cycles, because the market is likely underwriting lower growth while the revenue base could normalize faster than consensus expects. But if cybersecurity remediation drags through the rest of the year, the valuation reset may not be done, since investors will start discounting recurring operational risk rather than a single incident.

The contrarian view is that the selloff may be more about trust than fundamentals: the dividend increase and reaffirmed outlook help, but they do not fully offset the possibility of higher IT/security spending and occasional procedural disruption, both of which can compress margins for several quarters. In that sense, the stock can stay cheap longer than headline “undervaluation” implies, unless the company prints a clean recovery quarter that proves no durable share leakage to peers.

Key Decisions for Investors

• Hold off on chasing SYK outright for 2-4 weeks; wait for evidence of order normalization or channel checks showing no share loss. Risk/reward improves materially if the stock re-tests the lows and management guides to a clean second-half acceleration.
• If already long SYK, consider reducing 25-33% and replacing with a call spread 3-6 months out to keep upside exposure while capping downside if cyber remediation costs or demand leakage persist.
• Pair trade: long a medtech operator with limited operational disruption risk vs. short SYK for 1-2 quarters. The setup favors the cleaner-execution name if hospitals prioritize supply continuity and service reliability.
• For event-driven traders, buy SYK downside protection into the next earnings window only if implied volatility stays below realized post-incident volatility; otherwise use put spreads to express the risk that the recovery is slower than management implies.
• Reassess after the next quarter: if SYK shows a full revenue catch-up and margin recovery, it becomes a high-quality mean-reversion long with 12-month upside; if not, the market will likely re-rate it as a cyber-risk compounder rather than a temporary shock story.